deltatrials
Completed NA INTERVENTIONAL 3-arm NCT02459574

Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation (AVATAR-AF)

Sponsor: Imperial College London

Updated 8 times since 2017 Last updated: Oct 3, 2024 Started: May 1, 2015 Primary completion: Sep 30, 2018 Completion: Nov 27, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Heart Failure and Recurrent Atrial Fibrillation and is currently completed. Imperial College London leads this study, which shows 8 recorded versions since 2015 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Jan 2017 – ~Oct 2017 · 9 months · monthly snapshotRecruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshotActive Not Recruiting~Mar 2019 – ~Jan 2021 · 22 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshotCompleted~Nov 2024 – present · 20 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Nov 2024 — Present [monthly]

    Completed NA

  2. Sep 2024 — Nov 2024 [monthly]

    Completed NA

  3. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  4. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  5. Mar 2019 — Jan 2021 [monthly]

    Completed NA

    Status: Active Not RecruitingCompleted

Show 3 earlier versions
  1. Jun 2018 — Mar 2019 [monthly]

    Active Not Recruiting NA

  2. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting NA

    Status: RecruitingActive Not Recruiting

  3. Jan 2017 — Oct 2017 [monthly]

    Recruiting NA

    First recorded

May 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Imperial College London
Data source: Imperial College London

For direct contact, visit the study record on ClinicalTrials.gov .